NASDAQ:NMRA Neumora Therapeutics (NMRA) Stock Price, News & Analysis $0.60 -0.08 (-12.01%) Closing price 04:00 PM EasternExtended Trading$0.60 +0.00 (+0.47%) As of 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Neumora Therapeutics Stock (NASDAQ:NMRA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Neumora Therapeutics alerts:Sign Up Key Stats Today's Range$0.59▼$0.6950-Day Range$0.60▼$1.7352-Week Range$0.59▼$3.65Volume2.28 million shsAverage Volume1.64 million shsMarket Capitalization$112.03 millionP/E RatioN/ADividend YieldN/APrice Target$6.57Consensus RatingModerate Buy Company Overview Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for neurological and neuropsychiatric disorders. The company combines neuroscience research with data science and computational tools to identify disease mechanisms, discover potential drug targets and support the development of precision medicines for conditions affecting the brain. Neumora’s pipeline includes navacaprant, an investigational selective kappa opioid receptor antagonist being developed for major depressive disorder. The company is also advancing additional experimental programs aimed at addressing other central nervous system conditions, although the status and scope of these programs may change as clinical development progresses. Founded in 2019, Neumora is headquartered in the United States and became a publicly traded company on the Nasdaq under the symbol NMRA in 2023. Its operations are focused primarily on research and clinical development, with studies and development activities conducted through collaborations and clinical sites in relevant markets.AI Generated. May Contain Errors. Read More Neumora Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks77th Percentile Overall ScoreNMRA MarketRank™: Neumora Therapeutics scored higher than 77% of companies evaluated by MarketBeat, and ranked 213th out of 891 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingNeumora Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 1 strong buy rating, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialNeumora Therapeutics has a consensus price target of $6.57, representing about 1,002.2% upside from its current price of $0.60.Amount of Analyst CoverageNeumora Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Neumora Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Neumora Therapeutics are expected to grow in the coming year, from ($0.85) to ($0.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neumora Therapeutics is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Neumora Therapeutics is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeumora Therapeutics has a P/B Ratio of 0.96. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Neumora Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.08% of the float of Neumora Therapeutics has been sold short.Short Interest Ratio / Days to CoverNeumora Therapeutics has a short interest ratio ("days to cover") of 9.02.Change versus previous monthShort interest in Neumora Therapeutics has recently decreased by 13.05%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNeumora Therapeutics does not currently pay a dividend.Dividend GrowthNeumora Therapeutics does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment0.89 News SentimentNeumora Therapeutics has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Neumora Therapeutics this week, compared to 3 articles on an average week.Search Interest1 people have searched for NMRA on MarketBeat in the last 30 days. Company Ownership2.0 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Neumora Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $701,219.00 in company stock.Percentage Held by Insiders26.94% of the stock of Neumora Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions47.65% of the stock of Neumora Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Neumora Therapeutics' insider trading history. Receive NMRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neumora Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NMRA Stock News HeadlinesNeumora Therapeutics, Inc. (NASDAQ:NMRA) Receives $6.57 Average Price Target from AnalystsSeptember 24, 2026 | americanbankingnews.comNeumora Therapeutics, Inc. (NMRA)September 15, 2026 | finance.yahoo.comHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fraction of the cost? That's the core advantage options offer traders at every level. The Beginner's Guide to Options breaks down leverage, income strategies, and real trade examples in plain English — including a little-known approach many traders use to reduce costs and improve profit potential. Download your free copy before this offer expires.September 30 at 1:00 AM | Base Camp Trading (Ad)Top Neumora Executive Makes Notable Move With Insider Stock SaleAugust 21, 2026 | tipranks.comNeumora Therapeutics Announces CEO Transition and Q2 ResultsAugust 14, 2026 | tipranks.comNeumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdateAugust 14, 2026 | globenewswire.comNeumora Therapeutics Shares Rise on Positive Obesity Drug ResultsJuly 28, 2026 | marketwatch.comNeumora advances NMRA-215 with positive toxicology resultsJuly 27, 2026 | tipranks.comSee More Headlines NMRA Stock Analysis - Frequently Asked Questions How have NMRA shares performed this year? Neumora Therapeutics' stock was trading at $1.79 at the beginning of 2026. Since then, NMRA shares have decreased by 66.7% and is now trading at $0.5962. How were Neumora Therapeutics' earnings last quarter? Neumora Therapeutics, Inc. (NASDAQ:NMRA) posted its quarterly earnings data on Friday, August, 14th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.01. When did Neumora Therapeutics IPO? Neumora Therapeutics (NMRA) raised $250 million in an initial public offering on Friday, September 15th 2023. The company issued 14,710,000 shares at $16.00-$18.00 per share. How do I buy shares of Neumora Therapeutics? Shares of NMRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Neumora Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Neumora Therapeutics investors own include Vale (VALE), Paycom Software (PAYC), Clean Energy Fuels (CLNE), Centrus Energy (LEU), uniQure (QURE) and ThredUp (TDUP). Company Calendar Last Earnings8/14/2026Today9/30/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 2 weeks, NMRA's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:NMRA CIK1885522 Webneumoratx.com Phone857-760-0900FaxN/AEmployees63Year Founded2020Price Target and Rating Average Price Target for Neumora Therapeutics$6.57 High Price Target$14.00 Low Price Target$3.00 Potential Upside/Downside+1,002.2%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($1.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$236.93 million Net MarginsN/A Pretax MarginN/A Return on Equity-242.28% Return on Assets-131.32% Debt Debt-to-Equity Ratio1.19 Current Ratio4.50 Quick Ratio4.50 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.62 per share Price / Book0.96Miscellaneous Outstanding Shares187,900,000Free Float137,277,000Market Cap$112.03 million OptionableOptionable Beta2.71 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:NMRA) was last updated on 9/30/2026 by MarketBeat.com Staff. From Our PartnersHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredShould You Convert a Traditional IRA to a Roth After 60?Considering a Roth conversion after 60? The upside includes no income limits on conversions, potential tax-fre...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neumora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neumora Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
